MedTrace Logo

Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections

NCT06363370 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 322

Last updated 2024-04-12

No results posted yet for this study

Summary

To evaluate the efficacy and safety of interferon α1b (GB05) in the treatment of children under 2 years of age with respiratory syncytial virus infection.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

DRUG

Human interferon α1b Inhalation Solution

Participants will receive Human interferon α1b Inhalation Solution

DRUG

Inhalation Solution Placebo

Participants will receive Inhalation Solution Placebo

Sponsors & Collaborators

  • Kexing Biopharm Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Months
Max Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-27
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06363370 on ClinicalTrials.gov